Trial NCT00023920

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2012-02405
Secondary IDs: CDR0000068876 ID00-323 N01CM17003

Last trial update was posted on 2013-01-23

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Bevacizumab Cytarabine Idarubicin Immunoglobulins

MeSH Conditions

Blast Crisis Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid

Other Conditions

Blastic Phase Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Stopping Reasons

Administratively complete.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID